CPRX

CatalystC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

Most likely

B+

Bull case

70%

Probability

Target price

$31.55

+0.2% vs current

Base case

25%

Probability

Target price

$31.50

+0.0% vs current

B-

Bear case

Probability

Target price

$27.00

-14.3% vs current

AI sentiment snapshot

Latest data as of 2026-06-06

AI commentary

News flow is strongly positive but event-driven: the definitive $31.50 cash acquisition and the FIRDAPSE settlement dominate the tape, while the Q1 print confirmed healthy cash generation and a strong balance sheet. The current price is only slightly below the cash consideration, so most upside is spread compression rather than operating rerating. Analyst revision data are thin in the packet, which keeps this in monitoring mode rather than a fresh operating thesis.

RankAlpha Sentiment Codex - 2026-06-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07eventFIRDAPSE settlement removes the last major patent overhangMedium impact

Catalyst and SERB settled the remaining Hetero FIRDAPSE litigation, with no generic launch permitted in the United States before January 2035 if approved; this reduces a long-running downside overhang and ends the pending FIRDAPSE patent case [#SEC-8K-2026-05-07] [#SEC-10Q-2026-05-11].

2026-05-11catalystQ1 beat showed solid execution but no new guidanceMedium impact

Q1 2026 product revenue was $149.3 million and non-GAAP diluted EPS was $0.79; AP/Zacks reported that both adjusted EPS and revenue beat consensus, while the company said it would not provide forward guidance or host a call because of the May 7 transaction announcement [#PR-EARNINGS-2026-05-12] [#SEC-10Q-2026-05-11].

2026-09-30eventDefinitive $31.50 cash takeout anchors the stockMedium impact

Angelini agreed to acquire Catalyst for $31.50 per share in cash, with no financing condition and closing expected in Q3 2026; the merger spread is now the main trading driver rather than operating upside [#SEC-8K-2026-05-07] [#SEC-10Q-2026-05-11].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-06 • Updated nightlySource: Internal modelMethodology